YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation von Tsuji, Takahiro, Ozasa, Hiroaki, Aoki, Wataru, Aburaya, Shunsuke, Yamamoto Funazo, Tomoko, Furugaki, Koh, Yoshimura, Yasushi, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yasuda, Yuto, Nomizo, Takashi, Yoshida, Hironori, Sakamori, Yuichi, Wake, Hiroaki, Ueda, Mitsuyoshi, Kim, Young Hak, Hirai, Toyohiro

Volltext

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression von Yasuda, Yuto, Ozasa, Hiroaki, Kim, Young Hak, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yamamoto Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Sakamori, Yuichi, Nakajima, Naoki, Menju, Toshi, Yoshizawa, Akihiko, Date, Hiroshi, Hirai, Toyohiro

Volltext

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab von Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak

Volltext

Abstract 1271: ABCC11 is involved in resistance to alectinib von Funazo, Tomoko Yamamoto, Ozasa, Hiroaki, Tsuji, Takahiro, Furugaki, Koh, Yoshimura, Yasushi, Ajimizu, Hitomi, Yasuda, Yuto, Nomizo, Takashi, Sakamori, Yuichi, Yoshida, Hironori, Kim, Young Hak, Hirai, Toyohiro

Volltext

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X L expression von Yasuda, Yuto, Ozasa, Hiroaki, Kim, Young Hak, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yamamoto Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Sakamori, Yuichi, Nakajima, Naoki, Menju, Toshi, Yoshizawa, Akihiko, Date, Hiroshi, Hirai, Toyohiro

Volltext